Moomoo AI 已提取核心信息
Allarity Therapeutics, Inc. has filed an amended Schedule 13G/A with the Securities and Exchange Commission (SEC) on February 12, 2024, indicating a change in ownership by certain reporting persons. The filing was made by 3i, LP, 3i Management LLC, and Maier Joshua Tarlow, collectively referred to as the Reporting Persons, who now collectively own 653,377 shares of Allarity Therapeutics' common stock, representing 9.9% of the company. This ownership percentage is based on 5,886,934 outstanding shares as reported in the company's preliminary proxy statement filed on January 26, 2024. The shares include potential conversions and exercises of preferred stock, warrants, and a senior convertible note, all subject to beneficial ownership blockers that prevent ownership exceeding certain thresholds. The Reporting Persons have entered into a Joint Filing Agreement and have shared power to vote and dispose of the shares. The filing updates beneficial ownership information and amends previous disclosures, without indicating any intention to change or influence the control of Allarity Therapeutics.
Allarity Therapeutics, Inc. has filed an amended Schedule 13G/A with the Securities and Exchange Commission (SEC) on February 12, 2024, indicating a change in ownership by certain reporting persons. The filing was made by 3i, LP, 3i Management LLC, and Maier Joshua Tarlow, collectively referred to as the Reporting Persons, who now collectively own 653,377 shares of Allarity Therapeutics' common stock, representing 9.9% of the company. This ownership percentage is based on 5,886,934 outstanding shares as reported in the company's preliminary proxy statement filed on January 26, 2024. The shares include potential conversions and exercises of preferred stock, warrants, and a senior convertible note, all subject to beneficial ownership blockers that prevent ownership exceeding certain thresholds. The Reporting Persons have entered into a Joint Filing Agreement and have shared power to vote and dispose of the shares. The filing updates beneficial ownership information and amends previous disclosures, without indicating any intention to change or influence the control of Allarity Therapeutics.
Allarity Therapeutics, Inc.已于2024年2月12日向美国证券交易委员会（SEC）提交了经修订的附表13G/A，表明某些申报人的所有权发生了变化。该文件由3i、LP、3i Management LLC和Maier Joshua Tarlow提交，他们统称为申报人，他们现在共拥有Allarity Therapeutics的653,377股普通股，占该公司的9.9％的股份。该所有权百分比基于该公司于2024年1月26日提交的初步委托书中报告的5,886,934股已发行股份。这些股票包括优先股、认股权证和优先可转换票据的潜在转换和行使，所有这些都受实益所有权封锁的约束，以防止所有权超过一定门槛。申报人已签订联合申报协议，并拥有投票和处置股份的共同权力。该文件更新了受益所有权信息并修改了先前的披露，但没有表示有任何改变或影响Alarity Therapeutics控制权的意图。
Allarity Therapeutics, Inc.已于2024年2月12日向美国证券交易委员会（SEC）提交了经修订的附表13G/A，表明某些申报人的所有权发生了变化。该文件由3i、LP、3i Management LLC和Maier Joshua Tarlow提交，他们统称为申报人，他们现在共拥有Allarity Therapeutics的653,377股普通股，占该公司的9.9％的股份。该所有权百分比基于该公司于2024年1月26日提交的初步委托书中报告的5,886,934股已发行股份。这些股票包括优先股、认股权证和优先可转换票据的潜在转换和行使，所有这些都受实益所有权封锁的约束，以防止所有权超过一定门槛。申报人已签订联合申报协议，并拥有投票和处置股份的共同权力。该文件更新了受益所有权信息并修改了先前的披露，但没有表示有任何改变或影响Alarity Therapeutics控制权的意图。
有用
没用
